Articles

Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented new and significant data on HER-Vaxx at the World Congress of Gastrointestinal Cancer in Barcelona. Read More>

Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. Read more>

Gastric cancer ranks as the fourth leading cause of cancer-related deaths worldwide and the third in China. The overall five-year survival rate stands at approximately 20%. Radical gastrectomy has emerged as a prominent approach in the comprehensive treatment of gastric cancer, aiming to achieve a cure. Over time, advancements in clinical research have led to…

Summary Patients with upper GI cancers are in dire need of new therapeutic options. Astellas is sitting on a shoo-in approval for a brand new targeted therapy based on highly promising clinical trial data. An approval in this space could mean important new revenue inroads for the company. Read More>

CLAUDIN-18 Splice Variant 2 (claudin-18.2; CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.1 Multiple clinical trials of CLDN18.2-targeted therapies, including…

The FDA has granted orphan drug designation to ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), for the treatment of patients with gastric cancer and pancreatic cancer, according to a press release from developer Antengene Corporation Limited.1

Treatment with avelumab (Bavencio) plus GEN-001 in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma has demonstrated positive antitumor activity, according to an announcement by Genome & Company.1 The finding comes from a phase 2 study (NCT05419362) of GEN-001 in combination with avelumab, for which the primary end point is objective response rate (ORR),…

Chinese biotechnology company CARsgen Therapeutics has started a Phase II clinical trial of CT041 in the US, enrolling patients with Claudin18.2 (CLDN18.2) positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ). CT041 is an autologous chimeric antigen receptor (CAR) T-cell product candidate that targets the CLDN18.2 protein. The trial will evaluate CT041 in treating individuals with CLDN18.2…

A treatment currently under review by the Food and Drug Administration (FDA) for the treatment of patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma has been shown to improve patients’ overall survival, according to an announcement from the biotechnology company behind the treatment. Interim results of the RATIONALE 305 study showed…

Full Title A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) Purpose The purpose of this study is to assess the safety and effectiveness of the investigational drugs domvanalimab and zimberelimab given together with or without FOLFOX chemotherapy in people with inoperable…